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Summary objective To compare the cost-effectiveness of eﬂornithine and melarsoprol in the treatment of human
African trypanosomiasis.
method We used data from a Me ´decins Sans Frontie `res treatment project in Caxito, Angola to do a
formal cost-effectiveness analysis, comparing the efﬁciency of an eﬂornithine-based approach with
melarsoprol. Endpoints calculated were: cost per death avoided; incremental cost per additional life
saved; cost per years of life lost (YLL) averted; incremental cost per YLL averted. Sensitivity analysis was
done for all parameters for which uncertainty existed over the plausible range. We did an analysis with
and without cost of trypanocidal drugs included.
results Effectiveness was 95.6% for melarsoprol and 98.7% for eﬂornithine. Cost⁄patient was 504.6
for melarsoprol and 552.3 for eﬂornithine, cost per life saved was 527.5 USD for melarsoprol and
559.8 USD for eﬂornithine without cost of trypanocidal drugs but it increases to 600.4 USD and
844.6 USD per patient saved and 627.6 USD and 856.1 USD per life saved when cost of trypanocidal
drugs are included. Incremental cost-effectiveness ratio is 1596 USD per additional life saved and
58 USD per additional life year saved in the baseline scenario without cost of trypanocidal drugs but it
increases to 8169 USD per additional life saved and 299 USD per additional life year saved if costs of
trypanocidal drugs are included.
conclusion Eﬂornithine saves more lives than melarsoprol, but melarsoprol is slightly more cost-
effective. Switching from melarsoprol to eﬂornithine can be considered as a cost-effective option
according to the WHO choice criteria.
keywords human African trypanosomiasis, Trypanosoma brucei gambiense, eﬂornithine, melarsoprol,
cost-effectiveness
Introduction
Melarsoprol is still the most widely used drug for
treatment of second-stage Trypanosoma brucei gamb-
iense human African trypanosomiasis (HAT) despite its
toxicity, with an iatrogenic mortality between 3% and
10%. An alternative short-course melarsoprol regimen
showed equal effectiveness but also similar encephalop-
athy and death rates (Burri et al. 2000; Schmid et al.
2004, 2005). Robays et al. (2007) in a qualitative study
on perception of HAT control in Democratic Republic of
Congo (DRC) showed how people’s awareness of mel-
arsoprol toxicity leads to poor acceptance of active
screening programmes, and may partly explain why HAT
control programmes are ineffective in a number of high
prevalence settings such as the provinces of Bandundu
and Kasai in the DRC.
dl-Alpha-diﬂuoromethylornithine (DFMO) (eﬂorni-
thine) was proposed as an alternative to melarsoprol, but
decision makers long objected against its use as ﬁrst-line
drug in the treatment of second-stage HAT (Louis et al.
2003). Main arguments put forward were its allegedly
prohibitive cost, partly due to the need for a substantial
number of infusions, the high cost of the drug and the need
for additional skilled staff to maintain IV perfusions
around the clock in a ward full of HAT patients. Other
arguments evoked are the risks of sepsis when nursing care
is suboptimal and the danger of emerging resistance if
eﬂornithine is used in monotherapy. Politi et al. (1995)
considered ﬁrst-line treatment with eﬂornithine not a
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treatment in ﬁeld centres was demonstrated by Me ´dicins
Sans Frontie `res (MSF) in Kiri, Kajo-Keji County, Southern
Sudan (Chappuis et al. 2005). Free donation of eﬂornithine
by the drug company Aventis, now Sanoﬁ Aventis removed
one of the main obstacles. Also the recently emerging high
relapse rates with melarsoprol documented in Uganda
(Legros et al. 1999; Matovu et al. 2001), and in M’banza
Congo in Angola (Stanghellini & Josenando 2001) push
programmes to reconsider their treatment strategies, as
recently done in Angola and the Central African Republic.
We used data from a Me ´decins Sans Frontie `res treatment
project in Caxito, Angola to do a formal cost-effectiveness
analysis (CEA), comparing the efﬁciency of an
eﬂornithine-based approach with melarsoprol.
Methods
Study site and background
Between 2002 and 2006 MSF Belgium implemented a
HAT control programme in Caxito, Angola, treating 1200
sleeping sickness patients, of whom 690 were in second
stage. In 2004, eﬂornithine was introduced for treatment of
second-stage HAT because the high toxicity of melarsoprol
was considered unacceptable. The sources for the data
were programme input and output data provided by the
MSF programme in Angola. As the sleeping sickness ward
in Caxito was managed separately from the other wards in
the hospital, all reported data on staff and cost items
were speciﬁcally related to the care for sleeping sickness
patients. We compared formally the efﬁciency of HAT
treatment based on a regimen of 14 days IV (100 mg⁄kg
q.i.d.) eﬂornithine (Sanoﬁ Aventis) compared to melar-
soprol (Sanoﬁ Aventis), three series of four injections with
5 days of rest between each series, with a total dose of
32.4 mg⁄kg, together with prednisone 1 mg⁄kg⁄day. We
assumed that a case of relapse would be retreated with the
other drug. For the CEA, we used a health care system
perspective and only examined the cost of patient care for
HAT. This did not include the cost of active case ﬁnding
and diagnosis. Only blinded routinely available data
were used for the study. Permission was granted by the
Ministry of Health of Angola.
Costing of HAT care
All costs were converted to 2005 US dollars.
We conducted the baseline CEA assuming that the HAT-
speciﬁc drugs (trypanocides) were free of charge, as Sanoﬁ
Aventis has been donating them since 2001 to the HAT
control programmes per 5 year agreement. But, in the
sensitivity analysis, we checked a scenario that included the
cost of the trypanocides, rated at the preferential pricing
level that was charged before the donation programme
existed: 64 USD per average adult course for melarsoprol
(plausible range 50–100 USD) and 288 USD (plausible
range 250–400 USD) for eﬂornithine (Lutumba 2005). The
cost and quantities of all non-HAT-related drugs was
obtained from records kept by the MSF supply-centre at
the prices of 2005.
Transportation costs for most drugs were estimated at
7% of their value based on MSF freight reports. Because IV
ﬂuids and eﬂornithine are bulkier and heavier than other
drugs, we used a freight cost per kg for those two items
based on the prices from the actual freight reports (€ 1 per
kg). The MSF technical guideline on HAT was used to
estimate the quantities of drugs and medical supplies
(infusion sets, dressing material, etc.) used per patient,
including the treatment for major complications (arsenical
encephalopathy). Data obtained from the suppliers were
cross-checked with the data on the actual drug consump-
tion and the trends in patient case load, obtained from the
pharmacy records in Caxito.
Information on number and function of staff over the
years, wages and beneﬁts were taken from the MSF
administration records. As ﬁrst- and second-stage HAT
patients were treated in the same ward by the same staff
and ﬁrst-stage patients are treated with pentamidine, have
few side effects and need little nursing care. Therefore, we
assumed that 80% of staff time was devoted to the
treatment of second-stage patients. The HAT care centre
was staffed by one-half Full Time Equivalent (FTE)
medical doctor, one-fourth FTE nurse and one-fourth FTE
logistician.
Initially HAT patients were admitted in hospital tents
while a ward was being built. The building became only
operational at the end of the programme, but we included
its cost evenly over the period for our cost estimation. The
real building cost for this ward was spread over 20 years
and we used an annualization factor with a discount rate of
10%. We assumed a bed occupancy rate of 80%.
Effectiveness
Data on clinical outcomes (cure, side effects, mortality)
and patient characteristics such as age and sex had been
entered in Caxito by the clinician in charge in a
database specially developed for the care of sleeping
sickness (Epitryp, V.3, EPICENTRE). For the CEA we
could extract all relevant outcome data from this
database. For all clinical outcomes except for the relapse
rate, we used the actual value observed in Caxito in
the baseline CEA analysis, and obtained a range of
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Blum et al. 2001; Burri & Brun 2003). We used a
baseline case fatality rate of 1% (plausible range
0.5–2%) for eﬂornithine. For melarsoprol treatment we
used a proportion of encephalopathy of 10% (plausible
range 3–20%) and a case fatality rate due to the
encephalopathy of 40% (plausible range 20–100%).
For the model we assumed that all melarsoprol-related
deaths were caused by arsenical encephalopathy.
Because clinical follow-up was incomplete in the Caxito
treatment centre, we could not derive the relapse rates for
melarsoprol and eﬂornithine directly from the data.
Therefore, we used published relapse rates from the
literature in the base case scenario. As published relapse
rates vary, we used a baseline of 7% for both drugs with a
plausible range of 1–10 for eﬂornithine and of 3–30 for
melarsoprol (Pepin et al. 1994, 1989, 2000; Burri et al.
2000; Blum et al. 2001; Burri & Brun 2003).
Years of life lost averted (equivalent to years of life
gained) was used as the endpoint for the effectiveness
evaluation, as there was insufﬁcient information on HAT-
related disability to use the Disability Adjusted Life Year as
an endpoint. To establish YLL due to HAT disease, we
used the age distribution of our patients and used the
formula with non-zero discounting and age weighting
given by Murray and Lopez (1996) and used in the Global
Burden of Disease project (GBD) as follows:
YLL ¼ NCeðraÞ
 
ðb þ rÞ
2 eðbþrÞðLþaÞ½ ðb þ rÞðL þ aÞ 1 
h
 eðbþrÞa½ðbrÞa   1 
i
where r is the discount rate (GBD standard value is 0.03),
C is the age-weighting correction constant (GBD
standard value is 0.1658), b is the parameter from the
age-weighting function (GBD standard value is 0.04). We
used the spreadsheet available from the WHO website
(http://www.who.int/evidence).
Model
We built a decision tree using the software treeage pro
2006  (TreeAge Software, Inc., Figure 1). Sensitivity of all
parameters for which uncertainty existed was analysed
over the plausible range (mentioned between brackets in
the Results and Methods section). As endpoints we
calculated cost per death avoided; incremental cost per
additional life saved; cost per YLL averted; and incre-
mental cost per YLL averted.
Results
Costing
In case of melarsoprol treatment, the cost of baseline
adjuvant drugs was 19.7 USD, mainly due to oral
prednisolone (plausible range 10–30 USD). An episode of
encephalopathy required an additional 37.8 USD for
speciﬁc drugs (plausible range 20–50 USD). Eﬂorni-
thine treatment, on the other hand, required baseline
adjuvant drugs and medical supplies at a cost of
92.2 USD. We increased the transportation cost to
compensate for the 16 kg extra weight of eﬂornithine
and IV solutions.
Cured
Cured
Cured
Died
Died
Died
Died
Died
Relapsed
Relapsed
Relapsed
Survives
Survived
Efflornithine
Melarsoprol
Treatment
No or minor complications
Arsenical encephalopathy
Cured
Cured
Cured
Figure 1 Decision tree used during the
analysis.
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centre rose after introduction of eﬂornithine. For melar-
soprol the cost of auxiliary nursing staff per patient was
estimated at 209 USD per patient (USD 6.3⁄patient⁄day,
plausible range 5–15 USD). For eﬂornithine cost of
auxiliary nursing staff per patient was estimated at
306 USD (USD 15⁄patient⁄day, plausible range
5–20 USD). The cost of the expatriate staff was estimated
at USD 5.7⁄patient⁄day, plausible range 0–10 USD
based on real cost, including wages, social security and
travel, as budgeted by MSF.
Cost for the building was estimated at 1.6 USD⁄
patient⁄day.
Cost-effectiveness
Cost per death avoided, incremental cost per additional
live saved, cost per YLL avoided and incremental cost
per YLL avoided including and excluding the cost of
melarsoprol and eﬂornithine are presented in Table 1. It
shows that eﬂornithine saves more lives than melarsop-
rol, but the latter is slightly more cost-effective. Incre-
mental cost-effectiveness ratio (ICER) is the cost of
saving one additional life if the treatment policy would
change from melarsoprol to eﬂornithine. ICER is
1596 USD per additional life saved and 58 USD per
additional life year saved in the baseline scenario
without cost of trypanocidal drugs but it increases to
8169 USD per additional life saved and 299 USD per
additional life year saved if costs of trypanocidal drugs
are included.
Sensitivity was analysed including and excluding the
cost of trypanocidal drugs. Figure 2 shows that treatment
with eﬂornithine becomes more cost-effective when relapse
rates for melarsoprol exceed 16%. Eﬂornithine also
becomes the most cost-effective option when the lethality
of encephalopathy exceeds 70% (i.e. when the death rate
due to melarsoprol exceeds 7%).
Discussion
Both eﬂornithine and melarsoprol are effective and cost-
effective treatments for HAT, even if melarsoprol is
cheaper and its cost-effectiveness in second-stage HAT care
is slightly better in the baseline scenario. Eﬂornithine is a
cost-effective treatment, with 560 USD per life saved and
20 USD per life year saved. This is considered very
good value for money according to the WHO CHOICE
criteria (http://www.who.int/choice).
Higher adjuvant drug cost accounted for about half of
the increased cost of eﬂornithine, increased stafﬁng for the
other half. The additional workload of administering 24 h
perfusions was partly compensated by the fact that patients
needed less intensive monitoring for arsenical encepha-
lopathy. There is discussion on how to decide whether an
intervention is cost-effective or not. An ICER of 1595 USD
per additional life saved and USD 60 per additional life
year saved would still be considered cost-effective accord-
ing to the WHO choice criteria (Evans et al. 2005) and is
comparable to adding measles immunization and treatment
of active pneumonia to child care programmes (Edejer
et al. 2005) and tetanus vaccination in antenatal care
(Adam et al. 2005). It is deﬁnitely more cost-effective than
a lot of commonly implemented interventions, such as
meningitis vaccination, tetanus treatment and intensive
feeding programmes, while it is considerably cheaper than
ARV treatment for HIV. Another approach, proposed by
Murray et al. (2003) and Goldie et al. (2006), based on the
report of Commission for Macroeconomics and Health
(2001), investing in health for economic development is to
consider all intervention that cost less than the per capita
gross domestic product (GDP) for any given country as
Table 1 Cost per death avoided, incremental cost per additional live saved, cost per year life lost avoided and incremental cost (USD) per
year life lost avoided including and excluding the drug cost of melarsoprol and eﬂornithine
Cost of drug not included Cost of drug included
Melarsoprol Eﬂornithine Melarsoprol Eﬂornithine
Cost⁄patient 504.6 552.3 600.4 844.6
Effectiveness (%) 95.6 98.70 95.6 98.70
Cost⁄life saved 527.5 559.8 627.6 856.1
Cost⁄YLL averted 19.3 20.1 23.0 31.4
Incremental cost 47.7 244.2
Incremental effectiveness (%) 3 3
Incremental cost per additional life saved 1595.6 8168.8
Incremental cost per additional YLL averted 58.4 299.2
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three times GDP as cost-effective. For Angola (GDP
4300 USD) and Congo (GDP 700 USD) up this would
mean that the intervention can be considered as very cost-
effective.
The main argument for switching from melarsoprol to
eﬂornithine should not be searched for in CEA, it should be
done in the ﬁrst place because it avoids the melarsoprol-
related iatrogenic mortality. Robays et al. (2007) showed
that the mortality caused by melarsoprol has a profound
impact on the acceptability of the treatment and control
programmes, especially because people die who were
without symptoms but diagnosed infected by a screening
programme. Discussions with health staff in DRC revealed
that they did not dare to treat pregnant women because
they feared for their own security in case of complications.
We chose not to put the cost of eﬂornithine and
melarsoprol in the baseline calculations because free
donation of these products is assured at least until 2011.
Eﬂornithine is more difﬁcult to produce than melarsoprol,
but production of melarsoprol causes more environmental
hazard and environmental regulations make its produc-
tion difﬁcult if not impossible in Europe. National
programmes are unable to procure either without external
support and we strongly plead for a continuation of the
donation programme as long as it is needed. However,
even if Sanoﬁ Aventis gives both drugs for free for the
moment, costs will be incurred eventually. Therefore, we
also made the calculations using the preferential prices in
use before 2000. Our results differ considerably from
Politi et al. (1995), who included the cost of eﬂornithine
in the baseline calculations, assumed much lower hospi-
talization costs and used a baseline where relapsing
patients were not retreated, which we did not consider
acceptable. In Caxito, the long melarsoprol regimen
was used, while the new short regimen requires less
–2000
Relapse rate melarsoprol (0.03 to 0.3)
Arsenical encephalopathy (0.07 to 0.2)
Baseline drug cost eflornithine (46 to 120)
Relapse rate eflornithine (0.01 to 0.1)
Death rate arsenical encephalopathy (0.4 to 1)
Death rate eflornithine (0 to 0.02)
Building costs (0.78 to 3.12)
Drug cost melarsoprol (9 to 40)
Drug cost encephalitis (13 to 50)
Death rate relapses (0.05 to 0.1)
Cost of trypanocidal cost not included
Base case
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Figure 2 Tornado diagrams displaying
results on sensitivity analysis, incremental
cost effectiveness varying in function of the
plausible range for a number of parameters,
including and excluding cost of trypano-
cidal drugs.
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admission duration and on the implications for the
workload. The number of injections that need to be given
is comparable and the patient needs to be monitored in
the new regiment after the injections.
Cost of hospitalization is comparable with hospitaliza-
tion costs for Angola put forward by WHO on their
WHO CHOICE website despite the fact that we also
included the cost for expatriate staff. We included
expatriate staff because a transfer of competence is
needed to implement eﬂornithine treatment. Skills and
capacity needed to administer melarsoprol and dealing
with its complications are very speciﬁc for HAT treatment
and favour treatment in specialized centres. In contrast,
the technical capacity that is needed to administer
eﬂornithine is more generic, managing and safely admin-
istering perfusions should be a basic skill in all district
hospital settings and efforts to achieve this also help to
increase the overall quality of primary health care. Results
of implementation of eﬂornithine may be less good when
implemented outside a structure managed by an interna-
tional NGO. On the other hand, the 3% death rate for
melarsoprol in our study may also be lower than what
could be achieved in a more natural setting. A cost-
effectiveness study based on data coming from national
programmes would be useful.
Mortality rates for HAT treatment were relatively low in
Caxito compared to the death rates of 6% reported by
Burri et al. (2000) and Schmid et al. (2005) in a clinical
trial setting. In our sensitivity analysis we found that
eﬂornithine becomes equally cost-effective if the death rate
exceeds 7%. Eﬂornithine treatment is the most cost-
effective option when relapse rates exceed 16% and
continuing melarsoprol treatment in those circumstances
is, apart from being unethical, a waste of money. The
combination eﬂornithine⁄nifurtimox showed promising
preliminary results (Priotto et al. 2006) and an equivalence
trial is ongoing. This regimen is likely to be more feasible
and cost-effective and may prevent the emergence of
parasite resistance to eﬂornithine.
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